CCRB Logo

Trial History Detail on 2019-06-21

CUHK_CCT00439

2014-11-24

Prospective

2014.532

Department of Ophthalmology and Visual Sciences, the Chinese University of Hong Kong

Department of Ophthalmology and Visual Sciences, the Chinese University of Hong Kong

Nil

Not Applicable

Ms. Jennifer Tsoi

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, 3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon

3943 5869

jennifertsoi@cuhk.edu.hk

The Chinese University of Hong Kong

Hong Kong

Prof. Leung Christopher Kai Shun

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, 3/F, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon

39435846

cksleung@cuhk.edu.hk

The Chinese University of Hong Kong

Hong Kong

Progressive lamina cribrosa deformation – A biomarker for fast progressors in glaucoma?

Progressive lamina cribrosa deformation – A biomarker for fast progressors in glaucoma?

進展性篩板變形–診斷青光眼快速進展者的新指標?

Nil

Hong Kong

Yes

2014-11-20

Kowloon Central Cluster REC / Kowloon East Cluster REC

KC/KE-14-0198/FR-2

Glaucoma

Other

Drug and Procedure

The intervention is to use additional eye drops and/or laser procedure to achieve 20% intraocular pressure (IOP) lowering from baseline.
Drug: prostaglandin analogue, brimonidine and carbonic anhydrase inhibitor
Procedure: Selective Laser Trabeculoplasty

Eyedrop or laser procedure

every two months

Drug: prostaglandin analogue (PGA, once daily), brimonidine (three times daily), carbonic anhydrase

every two months

The comparative treatment is to continue the current treatment (observation or one topical IOP lowering medication) started before recruitment (see Inclusion Criteria).

NA (depends on the current treatment)

NA (depends on the current treatment)

every three months

NA (depends on the current treatment)

1.Age ≥18 years
2.Best corrected visual acuity ≥ 20/40
3.POAG patients diagnosed within 12 months without prior history of glaucoma surgical/laser procedure and receiving not more than one topical IOP lowering medication

IOP >30mmHg measured at any time points during the screening visit; high myopia (spherical error<-6.0D); moderate and advanced VF loss (VF MD <-6dB in the worse eye) or defects close to fixation (any one of the paracentral points with sensitivity <10dB); inability to perform reliable VF; suboptimal quality of SDOCT images (see SDOCT imaging); previous intraocular surgery other than uncomplicated cataract extraction; and diabetic retinopathy/maculopathy.

18

999

Both Male and Female

Interventional

Randomized

100 patients

Active

Open label

Parallel

3

2014-12-01

168

Recruiting

Proportion of eyes with VF progression

Proportion of eyes with RNFL progression
Rate of change visual field index
Rate of change of LC deformation before and after IOP reduction
Risk factors of LC deformation

No

2020-07-13

ChiCTR-IOR-14005592 

2014-12-03

Type Access Document Published On  
No documents yet.
  • Page 1 of 1.